Noema Pharma reports Phase 2 basimglurant results
Basimglurant cuts mean pain severity 67% in 53% of responders after 8 weeks; relapse risk is lower than placebo and registrational planning has begun.
See the latest news and media coverage for Noema Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing neurological therapeutics
noemapharma.comLast updated
Basimglurant cuts mean pain severity 67% in 53% of responders after 8 weeks; relapse risk is lower than placebo and registrational planning has begun.
EQT Life Sciences joins existing investors, and the capital supports four active Phase 2 trials with key data readouts anticipated in 2025.
The ALLEVIA-1 study met primary and all key secondary endpoints, with 57% of patients showing tic improvement and no serious adverse events.
Forbion and Jeito Capital co-led the oversubscribed round. Proceeds will advance CNS clinical-stage assets, and Nanna Lüneborg and Rachel Mears join the board.
EQT Life Sciences has led an extended Series B financing round in the Swiss biotech company Noema Pharma. With the extension, Noema Pharma has raised a total of 130 million...
This milestone underscores Sofinnova’s ability to form, build and grow companies around people and science that lead to life-changing innovations for patients Sofinnova Partners (“Sofinnova...
The proceeds from the Series B financing will be used for the further development of Noema Pharma's substances in the clinical phase, including the lead substance Basimglurant (NOE-101). Basel ...
Basel - Noema Pharma has received 103 million francs in an oversubscribed Series B financing round. The Basel-based company, specializing in debilitating diseases of the central nervous system...
Track Noema Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.